MICRON TECHNOLOGY, INC. | ||
(Exact name of registrant as specified in its charter) |
Delaware | 1-10658 | 75-1618004 | ||||||||||||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
8000 South Federal Way | ||
Boise, Idaho 83716-9632 | ||
(Address of principal executive offices and Zip Code) |
(208) 368-4000 | ||
(Registrant’s telephone number, including area code) |
Title of each class | Trading symbol | Name of each exchange on which registered | ||||||||||||
Common Stock, par value $0.10 per share | MU | Nasdaq Global Select Market |
Item 2.02. | Results of Operations and Financial Condition. |
Item 9.01. | Financial Statements and Exhibits. | ||||
(d) Exhibits. |
Exhibit No. | Description | |||||||
99.1 | ||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
MICRON TECHNOLOGY, INC. | |||||||||||
Date: | March 20, 2025 | By: | /s/ Mark Murphy | ||||||||
Name: | Mark Murphy | ||||||||||
Title: | Executive Vice President and Chief Financial Officer |
Contacts: | Satya Kumar |
Mark Plungy |
||||||
Investor Relations | Media Relations | |||||||
satyakumar@micron.com |
mplungy@micron.com | |||||||
(408) 450-6199 |
(408) 203-2910 |
Quarterly Financial Results | |||||||||||||||||||||||
(in millions, except per share amounts) | GAAP(1) |
Non-GAAP(2) |
|||||||||||||||||||||
FQ2-25 |
FQ1-25 |
FQ2-24 |
FQ2-25 |
FQ1-25 |
FQ2-24 |
||||||||||||||||||
Revenue | $ | 8,053 | $ | 8,709 | $ | 5,824 | $ | 8,053 | $ | 8,709 | $ | 5,824 | |||||||||||
Gross margin | 2,963 | 3,348 | 1,079 | 3,053 | 3,441 | 1,163 | |||||||||||||||||
percent of revenue | 36.8 | % | 38.4 | % | 18.5 | % | 37.9 | % | 39.5 | % | 20.0 | % | |||||||||||
Operating expenses | 1,190 | 1,174 | 888 | 1,046 | 1,047 | 959 | |||||||||||||||||
Operating income |
1,773 | 2,174 | 191 | 2,007 | 2,394 | 204 | |||||||||||||||||
percent of revenue | 22.0 | % | 25.0 | % | 3.3 | % | 24.9 | % | 27.5 | % | 3.5 | % | |||||||||||
Net income |
1,583 | 1,870 | 793 | 1,783 | 2,037 | 476 | |||||||||||||||||
Diluted earnings per share |
1.41 | 1.67 | 0.71 | 1.56 | 1.79 | 0.42 |
FQ3-25 | GAAP(1) Outlook |
Non-GAAP(2) Outlook |
||||||
Revenue |
$8.80 billion ± $200 million | $8.80 billion ± $200 million | ||||||
Gross margin |
35.5% ± 1.0% | 36.5% ± 1.0% | ||||||
Operating expenses |
$1.27 billion ± $15 million | $1.13 billion ± $15 million | ||||||
Diluted earnings per share |
$1.37 ± $0.10 | $1.57 ± $0.10 |
2nd Qtr. | 1st Qtr. | 2nd Qtr. | Six months ended | ||||||||||||||
February 27, 2025 |
November 28, 2024 |
February 29, 2024 |
February 27, 2025 |
February 29, 2024 |
|||||||||||||
Revenue | $ | 8,053 | $ | 8,709 | $ | 5,824 | $ | 16,762 | $ | 10,550 | |||||||
Cost of goods sold | 5,090 | 5,361 | 4,745 | 10,451 | 9,506 | ||||||||||||
Gross margin | 2,963 | 3,348 | 1,079 | 6,311 | 1,044 | ||||||||||||
Research and development | 898 | 888 | 832 | 1,786 | 1,677 | ||||||||||||
Selling, general, and administrative | 285 | 288 | 280 | 573 | 543 | ||||||||||||
Other operating (income) expense, net | 7 | (2) | (224) | 5 | (239) | ||||||||||||
Operating income (loss) | 1,773 | 2,174 | 191 | 3,947 | (937) | ||||||||||||
Interest income | 108 | 107 | 130 | 215 | 262 | ||||||||||||
Interest expense | (112) | (118) | (144) | (230) | (276) | ||||||||||||
Other non-operating income (expense), net | (11) | (11) | (7) | (22) | (34) | ||||||||||||
1,758 | 2,152 | 170 | 3,910 | (985) | |||||||||||||
Income tax (provision) benefit | (177) | (283) | 622 | (460) | 549 | ||||||||||||
Equity in net income (loss) of equity method investees | 2 | 1 | 1 | 3 | (5) | ||||||||||||
Net income (loss) | $ | 1,583 | $ | 1,870 | $ | 793 | $ | 3,453 | $ | (441) | |||||||
Earnings (loss) per share | |||||||||||||||||
Basic | $ | 1.42 | $ | 1.68 | $ | 0.72 | $ | 3.10 | $ | (0.40) | |||||||
Diluted | 1.41 | 1.67 | 0.71 | 3.08 | (0.40) | ||||||||||||
Number of shares used in per share calculations | |||||||||||||||||
Basic | 1,115 | 1,111 | 1,104 | 1,113 | 1,102 | ||||||||||||
Diluted | 1,123 | 1,122 | 1,114 | 1,123 | 1,102 |
As of | February 27, 2025 |
November 28, 2024 |
August 29, 2024 |
||||||||
Assets | |||||||||||
Cash and equivalents | $ | 7,552 | $ | 6,693 | $ | 7,041 | |||||
Short-term investments | 663 | 895 | 1,065 | ||||||||
Receivables | 6,504 | 7,423 | 6,615 | ||||||||
Inventories | 9,007 | 8,705 | 8,875 | ||||||||
Other current assets | 963 | 777 | 776 | ||||||||
Total current assets | 24,689 | 24,493 | 24,372 | ||||||||
Long-term marketable investments | 1,375 | 1,156 | 1,046 | ||||||||
Property, plant, and equipment | 42,528 | 41,476 | 39,749 | ||||||||
Operating lease right-of-use assets | 637 | 622 | 645 | ||||||||
Intangible assets | 423 | 419 | 416 | ||||||||
Deferred tax assets | 552 | 474 | 520 | ||||||||
Goodwill | 1,150 | 1,150 | 1,150 | ||||||||
Other noncurrent assets | 1,699 | 1,671 | 1,518 | ||||||||
Total assets | $ | 73,053 | $ | 71,461 | $ | 69,416 | |||||
Liabilities and equity | |||||||||||
Accounts payable and accrued expenses | $ | 6,176 | $ | 7,126 | $ | 7,299 | |||||
Current debt | 504 | 533 | 431 | ||||||||
Other current liabilities | 1,197 | 1,356 | 1,518 | ||||||||
Total current liabilities | 7,877 | 9,015 | 9,248 | ||||||||
Long-term debt | 13,851 | 13,252 | 12,966 | ||||||||
Noncurrent operating lease liabilities | 599 | 588 | 610 | ||||||||
Noncurrent unearned government incentives | 836 | 570 | 550 | ||||||||
Other noncurrent liabilities | 1,257 | 1,239 | 911 | ||||||||
Total liabilities | 24,420 | 24,664 | 24,285 | ||||||||
Commitments and contingencies | |||||||||||
Shareholders’ equity | |||||||||||
Common stock | 126 | 126 | 125 | ||||||||
Additional capital | 12,711 | 12,317 | 12,115 | ||||||||
Retained earnings | 43,839 | 42,427 | 40,877 | ||||||||
Treasury stock | (7,852) | (7,852) | (7,852) | ||||||||
Accumulated other comprehensive income (loss) | (191) | (221) | (134) | ||||||||
Total equity | 48,633 | 46,797 | 45,131 | ||||||||
Total liabilities and equity | $ | 73,053 | $ | 71,461 | $ | 69,416 |
Six months ended | February 27, 2025 |
February 29, 2024 |
||||||
Cash flows from operating activities | ||||||||
Net income (loss) | $ | 3,453 | $ | (441) | ||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
||||||||
Depreciation expense and amortization of intangible assets | 4,109 | 3,839 | ||||||
Stock-based compensation |
469 | 401 | ||||||
Change in operating assets and liabilities: |
||||||||
Receivables | 338 | (1,759) | ||||||
Inventories | (132) | (57) | ||||||
Other current assets |
(204) | (799) | ||||||
Accounts payable and accrued expenses | (714) | 573 | ||||||
Other current liabilities |
(321) | 706 | ||||||
Other | 188 | 157 | ||||||
Net cash provided by operating activities | 7,186 | 2,620 | ||||||
Cash flows from investing activities | ||||||||
Expenditures for property, plant, and equipment | (7,261) | (3,180) | ||||||
Purchases of available-for-sale securities | (816) | (465) | ||||||
Proceeds from government incentives | 1,028 | 234 | ||||||
Proceeds from maturities and sales of available-for-sale securities |
874 | 726 | ||||||
Other | (125) | (24) | ||||||
Net cash provided by (used for) investing activities | (6,300) | (2,709) | ||||||
Cash flows from financing activities | ||||||||
Repayments of debt | (2,626) | (1,101) | ||||||
Payments of dividends to shareholders | (261) | (256) | ||||||
Payments on equipment purchase contracts | — | (82) | ||||||
Proceeds from issuance of debt |
2,682 | 999 | ||||||
Other | (121) | (18) | ||||||
Net cash provided by (used for) financing activities | (326) | (458) | ||||||
Effect of changes in currency exchange rates on cash, cash equivalents, and restricted cash |
(49) | (8) | ||||||
Net increase (decrease) in cash, cash equivalents, and restricted cash | 511 | (555) | ||||||
Cash, cash equivalents, and restricted cash at beginning of period | 7,052 | 8,656 | ||||||
Cash, cash equivalents, and restricted cash at end of period | $ | 7,563 | $ | 8,101 |
2nd Qtr. | 1st Qtr. | 2nd Qtr. | |||||||||
February 27, 2025 |
November 28, 2024 |
February 29, 2024 |
|||||||||
GAAP gross margin | $ | 2,963 | $ | 3,348 | $ | 1,079 | |||||
Stock-based compensation | 89 | 90 | 80 | ||||||||
Other | 1 | 3 | 4 | ||||||||
Non-GAAP gross margin | $ | 3,053 | $ | 3,441 | $ | 1,163 | |||||
GAAP operating expenses | $ | 1,190 | $ | 1,174 | $ | 888 | |||||
Stock-based compensation | (144) | (127) | (129) | ||||||||
Patent cross-license agreement gain | — | — | 200 | ||||||||
Non-GAAP operating expenses | $ | 1,046 | $ | 1,047 | $ | 959 | |||||
GAAP operating income |
$ | 1,773 | $ | 2,174 | $ | 191 | |||||
Stock-based compensation | 233 | 217 | 209 | ||||||||
Patent cross-license agreement gain | — | — | (200) | ||||||||
Other | 1 | 3 | 4 | ||||||||
Non-GAAP operating income |
$ | 2,007 | $ | 2,394 | $ | 204 | |||||
GAAP net income |
$ | 1,583 | $ | 1,870 | $ | 793 | |||||
Stock-based compensation | 233 | 217 | 209 | ||||||||
Patent cross-license agreement gain | — | — | (200) | ||||||||
Other | 4 | — | 2 | ||||||||
Estimated tax effects of above and other tax adjustments |
(37) | (50) | (328) | ||||||||
Non-GAAP net income |
$ | 1,783 | $ | 2,037 | $ | 476 | |||||
GAAP weighted-average common shares outstanding - Diluted |
1,123 | 1,122 | 1,114 | ||||||||
Adjustment for stock-based compensation |
20 | 16 | 20 | ||||||||
Non-GAAP weighted-average common shares outstanding - Diluted |
1,143 | 1,138 | 1,134 | ||||||||
GAAP diluted earnings per share |
$ | 1.41 | $ | 1.67 | $ | 0.71 | |||||
Effects of the above adjustments |
0.15 | 0.12 | (0.29) | ||||||||
Non-GAAP diluted earnings per share |
$ | 1.56 | $ | 1.79 | $ | 0.42 |
2nd Qtr. | 1st Qtr. | 2nd Qtr. | |||||||||
February 27, 2025 |
November 28, 2024 |
February 29, 2024 |
|||||||||
GAAP net cash provided by operating activities |
$ | 3,942 | $ | 3,244 | $ | 1,219 | |||||
Expenditures for property, plant, and equipment |
(4,055) | (3,206) | (1,384) | ||||||||
Payments on equipment purchase contracts | — | — | (26) | ||||||||
Proceeds from sales of property, plant, and equipment | 7 | 9 | 13 | ||||||||
Proceeds from government incentives |
963 | 65 | 149 | ||||||||
Investments in capital expenditures, net | (3,085) | (3,132) | (1,248) | ||||||||
Adjusted free cash flow |
$ | 857 | $ | 112 | $ | (29) |
FQ3-25 |
GAAP Outlook | Adjustments | Non-GAAP Outlook | ||||||||||||||||||||
Revenue |
$8.80 billion ± $200 million |
— | $8.80 billion ± $200 million |
||||||||||||||||||||
Gross margin |
35.5% ± 1.0% |
1.0% |
A | 36.5% ± 1.0% |
|||||||||||||||||||
Operating expenses |
$1.27 billion ± $15 million |
$144 million |
B | $1.13 billion ± $15 million |
|||||||||||||||||||
Diluted earnings per share(1) |
$1.37 ± $0.10 |
$0.20 |
A, B, C | $1.57 ± $0.10 |
Non-GAAP Adjustments
(in millions)
|
|||||||||||||||||||||||
A |
Stock-based compensation – cost of goods sold |
$ | 106 | ||||||||||||||||||||
B |
Stock-based compensation – research and development |
89 | |||||||||||||||||||||
B |
Stock-based compensation – sales, general, and administrative |
55 | |||||||||||||||||||||
C |
Tax effects of the above items and other tax adjustments | (29) | |||||||||||||||||||||
$ | 221 |